




PHARMACEUTICAL 2023

DYNAVAX TECHNOLOGIES CORP

Rank 112 of 446





PHARMACEUTICAL 2023

DYNAVAX TECHNOLOGIES CORP Rank 112 of 446



The relative strengths and weaknesses of DYNAVAX TECHNOLOGIES CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of DYNAVAX TECHNOLOGIES CORP compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 125% points. The greatest weakness of DYNAVAX TECHNOLOGIES CORP is the variable Other Liabilities, reducing the Economic Capital Ratio by 47% points.

The company's Economic Capital Ratio, given in the ranking table, is 186%, being 143% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	916,985
Cost of Goods Sold	0
Intangible Assets	2,006
Liabilities, Current	150,074
Liabilities, Non-Current	33,185
Other Assets	29,263
Other Compr. Net Income	-3,172
Other Expenses	267,227
Other Liabilities	221,578
Other Net Income	8,023
Other Revenues	730,368
Property and Equipment	37,596
Research and Development	46,600
Selling, General and Administrative Expense	131,408

Output Variable	Value in 1000 USD
Assets	985,850
Liabilities	404,837
Expenses	445,235
Revenues	730,368
Stockholders Equity	581,013
Net Income	293,156
Comprehensive Net Income	291,570
Economic Capital Ratio	186%